Great Novel Therapeutics Biotech & Medicals (TPEX:7427)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
33.50
-0.45 (-1.33%)
Aug 15, 2025, 1:57 PM CST
-1.33%
Market Cap1.46B
Revenue (ttm)1.78M
Net Income (ttm)-87.75M
Shares Out43.64M
EPS (ttm)-2.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume58,788
Average Volume104,069
Open33.95
Previous Close33.95
Day's Range33.20 - 34.00
52-Week Range30.10 - 50.00
Beta-0.07
RSI36.68
Earnings DateAug 12, 2025

About TPEX:7427

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. It develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei City, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 18
Stock Exchange Taipei Exchange
Ticker Symbol 7427
Full Company Profile

Financial Performance

In 2024, TPEX:7427's revenue was 1.69 million, a decrease of -65.26% compared to the previous year's 4.85 million. Losses were -104.92 million, 72.0% more than in 2023.

Financial Statements

News

There is no news available yet.